Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial

Di Giacomo, AM; Covre, A; Finotello, F; Rieder, D; Danielli, R; Sigalotti, L; Giannarelli, D; Petitprez, F; Lacroix, L; Valente, M; Cutaia, O; Fazio, C; Amato, G; Lazzeri, A; Monterisi, S; Miracco, C; Coral, S; Anichini, A; Bock, C; Nemc, A; Oganesia

Maio, M (reprint author), Univ Hosp Siena, Ctr Immunooncol Med Oncol & Immunotherapy, Dept Oncol, Viale Mario Bracci 16, I-53100 Siena, Italy.

CLINICAL CANCER RESEARCH, 2019; 25 (24): 7351

Abstract

Purpose: The immunomodulatory activity of DNA hypomethylating agents (DHAs) suggests they may improve the effectiveness of cancer immunotherapies. The......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索